Prenetics Global Limited (PRE) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
↓
N/A
—
5yr avg: 115.65
30Y Low18.6·High18.6
P/B Ratio
↑
1.28
↑+94% vs avg
5yr avg: 0.66
30Y Low0.3·High1.3
ROE
↑
-33.7%
↓+18% vs avg
5yr avg: -41.0%
30Y Low-120%·High-8%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low12.0·High12.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Prenetics Global Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $242M | $221M | $74M | $66M | $152M | $426M | — | — |
| Enterprise Value | $213M | $191M | $27M | $23M | $12M | $883M | — | — |
| P/E Ratio → | -3.83 | — | — | — | — | — | — | — |
| P/S Ratio | 2.62 | 2.40 | 2.41 | 3.06 | 11.55 | 34.01 | — | — |
| P/B Ratio | 1.28 | 1.27 | 0.43 | 0.32 | 0.62 | — | — | — |
| P/FCF | — | — | — | — | 18.61 | 212.69 | — | — |
| P/OCF | — | — | — | — | 10.48 | 31.77 | — | — |
P/E links to full P/E history page with 30-year chart
PRE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.07 | 0.89 | 1.06 | 0.92 | 70.43 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 1.48 | 440.39 | — | — |
PRE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Prenetics Global Limited earns an operating margin of -40.5%. Operating margins have expanded from -238.7% to -40.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -33.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.0% | 53.0% | 50.3% | 40.6% | 27.5% | 28.7% | 40.4% | 29.4% |
| Operating Margin | -40.5% | -40.5% | -157.2% | -238.7% | -501.5% | -452.1% | -1.5% | -225.3% |
| Net Profit Margin | -63.1% | -63.1% | -151.2% | -288.5% | -1446.8% | -1388.4% | -3.0% | -218.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -33.7% | -33.7% | -24.3% | -27.7% | -78.2% | — | -8.1% | -119.5% |
| ROA | -28.0% | -28.0% | -19.8% | -22.2% | -82.7% | -153.0% | -3.6% | -67.8% |
| ROIC | -20.8% | -20.8% | -24.8% | -28.8% | -62.3% | -95.3% | -3.7% | -229.9% |
| ROCE | -21.2% | -21.2% | -24.6% | -22.1% | -38.3% | -93.2% | -4.0% | -117.0% |
PRE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $32M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.03 | — | 0.55 | 0.09 |
| Debt / EBITDA | — | — | — | — | — | — | 11.98 | — |
| Net Debt / Equity | — | -0.17 | -0.27 | -0.21 | -0.58 | — | 0.09 | -0.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | 1.86 | — |
| Debt / FCF | — | — | — | — | -17.13 | 227.71 | — | — |
| Interest Coverage | -155.12 | -155.12 | -237.16 | -433.78 | -272.82 | -1341.78 | -16.71 | -299.80 |
Net cash position: cash ($32M) exceeds total debt ($2M)
PRE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Prenetics Global Limited's current ratio of 3.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.37x to 3.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.01 | 3.01 | 2.36 | 2.37 | 4.23 | 1.82 | 0.93 | 1.31 |
| Quick Ratio | 2.76 | 2.76 | 2.18 | 2.29 | 4.15 | 1.70 | 0.84 | 1.27 |
| Cash Ratio | 2.22 | 2.22 | 1.72 | 1.84 | 3.22 | 0.77 | 0.31 | 0.99 |
| Asset Turnover | — | 0.45 | 0.14 | 0.09 | 0.04 | 0.08 | 0.83 | 0.31 |
| Inventory Turnover | 6.16 | 6.16 | 2.32 | 4.13 | 2.11 | 1.31 | 8.63 | 11.90 |
| Days Sales Outstanding | — | 11.78 | 66.81 | 88.87 | 1178.29 | 1370.29 | 129.34 | 114.34 |
PRE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Prenetics Global Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 5.4% | 0.5% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.8% | 1.9% | 0.4% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.8% | 1.9% | 0.4% | 0.0% | — | — |
| Shares Outstanding | — | $14M | $13M | $11M | $5M | $4M | $7M | $7M |
Peer Comparison
Compare PRE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PREYou | $242M | -3.8 | — | — | 53.0% | -40.5% | -33.7% | -20.8% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 NTRA | $30B | -140.6 | — | 427.2 | 60.3% | -13.1% | -19.4% | -33.3% | — |
 CSTL | $750M | -29.8 | — | 26.5 | 68.7% | -12.4% | -5.2% | -8.5% | — |
 QDEL | $746M | -0.7 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 AHCO | $2B | -21.9 | 5.6 | 7.1 | 17.5% | 5.7% | -4.6% | 4.0% | 3.2 |
 HIMS | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 MYRG | $7B | 60.4 | 30.7 | 30.5 | 11.5% | 4.4% | 18.8% | 18.3% | 0.5 |
 TMO | $176B | 26.7 | 19.0 | 27.9 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.7 | 18.1 | 23.5 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 IQV | $30B | 22.5 | 12.9 | 14.6 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See PRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRE vs EXAS
Side-by-side business, growth, and profitability comparison vs Exact Sciences Corporation.
Start ComparisonPRE — Frequently Asked Questions
Quick answers to the most common questions about buying PRE stock.
What is Prenetics Global Limited's P/E ratio?
Prenetics Global Limited's current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.
What is Prenetics Global Limited's ROE?
Prenetics Global Limited's return on equity (ROE) is -33.7%. The historical average is -48.6%.
Is PRE stock overvalued?
Based on historical data, Prenetics Global Limited is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Prenetics Global Limited's profit margins?
Prenetics Global Limited has 53.0% gross margin and -40.5% operating margin.